Previous 10 | Next 10 |
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2020. First-quarter 2020 net sales were $571.6 million, an increase of 3.2 percent compared t...
Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA)...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it was granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 Total Ab test, the firs...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first quarter 2020 on Wednesday, May 6, 2020, following the close of the market. The company will discuss these results in a confer...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the commercial launch of its SARS-CoV-2 Total Ab test, a blood-based immunoassay kit to help determine if an individual has developed antibodies to SARS-...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cel...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company is launching a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. P...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies published this month , ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR (ddPCR) S...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its Real-Time qPCR products are being used by testing laboratories globally to screen for COVID-19. Multiple testing laboratories are utilizing ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that through its Exact Diagnostics product line Bio-Rad has launched a SARS CoV-2 Standard to support laboratory assay validation of coronavirus (COVID-1...
News, Short Squeeze, Breakout and More Instantly...
Bio-Rad Laboratories Inc. Cl B Company Name:
BIOB Stock Symbol:
NYSE Market:
Bio-Rad Laboratories Inc. Cl B Website:
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. ...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferi...